Mesenchymal Stem Cell: A Friend or Foe in Anti-Tumor Immunity
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Mesenchymal stem cells (MSCs) are self-renewable, multipotent stem cells that regulate the phenotype and function of all immune cells that participate in anti-tumor immunity. MSCs modulate the antigen-presenting properties of dendritic cells, affect chemokine and cytokine production in macrophages and CD4+ T helper cells, alter the cytotoxicity of CD8+ T lymphocytes and natural killer cells and regulate the generation and expansion of myeloid-derived suppressor cells and T regulatory cells. As plastic cells, MSCs adopt their phenotype and function according to the cytokine profile of neighboring tumor-infiltrated immune cells. Depending on the tumor microenvironment to which they are exposed, MSCs may obtain pro- and anti-tumorigenic phenotypes and may enhance or suppress tumor growth. Due to their tumor-homing properties, MSCs and their exosomes may be used as vehicles for delivering anti-tumorigenic agents in tumor cells, attenuating their viability and invasive characteristics. Since many factors affect the phenotype and function of MSCs in the tumor microenvironment, a better understanding of signaling pathways that regulate the cross-talk between MSCs, immune cells and tumor cells will pave the way for the clinical use of MSCs in cancer immunotherapy. In this review article, we summarize current knowledge on the molecular and cellular mechanisms that are responsible for the MSC-dependent modulation of the anti-tumor immune response and we discuss different insights regarding therapeutic potential of MSCs in the therapy of malignant diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MSCs by secretion of CXCL3, HGF, and IL-6 have a role in myeloid suppressor cell (MDSC) differentiation and in this way suppress the immune system in TME.”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In innate immunity, BM-MSCs express C3aR and C5aR (Complement system receptors), as anaphylatoxin receptors, for recruitment of MSCs to the sites of damage or lesions [72, 78, 79].”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Specifically, human umbilical cord-derived MSC EVs (UC-MSC EVs) contain miRNA-16-5p and miRNA-3940-5p cargos that reduce the metastatic potential of tumor cells.”
From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies recognized that miRNAs delivered via MSC EVs were able to inhibit the metastatic potential of tumors, as well as suppress tumor growth, angiogenesis, and invasion [25].”
From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As a result, MSCs have the potential to enhance a pro-tumor microenvironment [25].”
From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [25]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Razeghian, E., Margiana, R., Chupradit, S., Bokov, D. O., Abdelbasset, W. K., Marofi, F., Shariatzadeh, S., Tosan, F., & Jarahian, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.721174 · Cited by 28
RetractedHassanzadeh, A., Altajer, A. H., Rahman, H. S., Saleh, M. M., Bokov, D. O., Abdelbasset, W. K., Marofi, F., Zamani, M., Yaghoubi, Y., Yazdanifar, M., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.686453 · Cited by 24 · cited 3×
“Despite the fact that a large number of studies demonstrated the pro-tumorigenic potential of MSCs, it has to be noted that MSCs are not constitutively immunosuppressive cells [12].”
BackgroundInfluentialRetractedMyeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine
Srivastava, M. K., Sinha, P., Clements, V. K., Rodriguez, P., & Ostrand-Rosenberg, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2587 · Cited by 949 · cited 2×
“Accordingly, T cells use their plasma membrane neutral amino acid transporter to import cysteine released from DCs [15].”
BackgroundHarrell, C. R., Jovicic, N., Djonov, V., Arsenijevic, N., & Volarevic, V. (2019) · Cells · doi:10.3390/cells8121605 · Cited by 795
Self-citationTherapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer
Weng, Z., Zhang, B., Wu, C., Yu, F., Han, B., Li, B., & Li, L. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01141-y · Cited by 405 · cited 3×
“Since MSCs represent an important cellular constituent of the tumor microenvironment and are able to modulate the phenotype and function of all immune cells that participate in the anti-tumor immune response [9,10], a large number of experimental studies investigated the molecular mechanisms that were responsible for…”
BackgroundDavies, L. C., Heldring, N., Kadri, N., & Le Blanc, K. (2017) · Stem Cells · doi:10.1002/stem.2509 · Cited by 349 · cited 1×
“Additionally, TNF-α and IFN-γ-primed MSC2 express and secrete PDL1 and PDL2, which suppress the proliferation of TNF-α and IFN-γ-producing T cells and promote the generation and expansion of immunosuppressive Tregs [31].”
BackgroundPakravan, K., Babashah, S., Sadeghizadeh, M., Mowla, S. J., Mossahebi-Mohammadi, M., Ataei, F., Dana, N., & Javan, M. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0335-7 · Cited by 346
Mesenchymal Stem Cells: A Friend or Foe in Immune-Mediated Diseases
Gazdic, M., Volarevic, V., Arsenijevic, N., & Stojkovic, M. (2015) · Stem Cell Reviews and Reports · doi:10.1007/s12015-014-9583-3 · Cited by 248 · cited 1×
“As plastic cells, MSCs may adopt phenotype and function under the influence of the biological factors to which they are exposed [30].”
BackgroundContribution of regulatory T cells to cancer: A review
Najafi, M., Farhood, B., & Mortezaee, K. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27553 · Cited by 195 · cited 2×
“Tregs and MDSCs express cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and PDL1 and produce immunosuppressive cytokines (IL-10 and transforming growth factor beta (TGF-β)) that inhibit the proliferation, activation and effector function of CTLs and NK cells, while M2 macrophages and N2 neutrophils secrete pro-an…”
BackgroundResultMesenchymal Stem Cells Use IDO to Regulate Immunity in Tumor Microenvironment
Ling, W., Zhang, J., Yuan, Z., Ren, G., Zhang, L., Chen, X., Rabson, A. B., Roberts, A. I., Wang, Y., & Shi, Y. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1656 · Cited by 194 · cited 2×
“Additionally, in the tumor microenvironment, MSC-sourced IDO prevents the trans-differentiation of Tregs in anti-tumorigenic, Th17-like cells [26].”
BackgroundNext frontier in tumor immunotherapy: macrophage-mediated immune evasion
Qiu, Y., Chen, T., Hu, R., Zhu, R., Li, C., Ruan, Y., Xie, X., & Li, Y. (2021) · Biomarker Research · doi:10.1186/s40364-021-00327-3 · Cited by 158 · cited 3×
“proteases lyse tumor cells while M1 macrophage-sourced chemokines attract cytotoxic CD8+ CTLs and natural killer (NK) cells in the tumor microenvironment [1,3].”
BackgroundXu, Y., Shen, L., Li, F., Yang, J., Wan, X., & Ouyang, M. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28747 · Cited by 150
Harrell, C. R., Gazdic, M., Fellabaum, C., Volarevic, A., Djonov, V., Arsenijević, A., & Volarević, V. (2018) · Advances in experimental medicine and biology · doi:10.1007/5584_2018_306 · Cited by 130 · cited 6×
“MSCs affect the antigen-presenting properties of DCs, B cells and macrophages, modulate the phagocytic ability of neutrophils and monocytes, change the polarization of macrophages, modify the xcytotoxic properties of NK cells and regulate the proliferation, activation and effector functions of CD4+ and CD8+ T cells [7…”
BackgroundSelf-citationLayek, B., Sadhukha, T., Panyam, J., & Prabha, S. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0682 · Cited by 126
Therapeutic Use of Mesenchymal Stem Cell-Derived Exosomes: From Basic Science to Clinics
Harrell, C. R., Jovicic, N., Djonov, V., & Volarevic, V. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12050474 · Cited by 126 · cited 1×
“Several lines of evidence demonstrated that the administration of MSC-derived extracellular vesicles (MSC-EVs), which contain MSC-sourced anti-tumorigenic microRNAs (miRNAs), could represent a potentially new therapeutic approach in the MSC-based immunotherapy of tumors [10,13,37].”
BackgroundSelf-citationThe Cross-Talk between Mesenchymal Stem Cells and Immune Cells in Tissue Repair and Regeneration
Harrell, C. R., Djonov, V., & Volarević, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052472 · Cited by 124 · cited 3×
“Additionally, MSCs, in a juxtacrine and paracrine manner, induce the generation and expansion of immunosuppressive Tregs and MDSCs, playing a crucially important role in the alleviation of on-going inflammation [7,8].”
BackgroundSelf-citationMathew, E., Brannon, A. L., Del Vecchio, A., Garcia, P. E., Penny, M. K., Kane, K. T., Vinta, A., Buckanovich, R. J., & di Magliano, M. P. (2016) · Neoplasia · doi:10.1016/j.neo.2016.01.005 · Cited by 121 · cited 5×
“Immunosuppressive cytokines produced by M2 TAMs and MSC2 down-regulated the anti-tumor immune response, enabling immune evasion and the uncontrolled proliferation of pancreatic cancer cells [17].”
BackgroundResultInfluentialHuman stem cell research and regenerative medicine--present and future
Volarevic, V., Ljujic, B., Stojkovic, P., Lukic, A., Arsenijevic, N., & Stojkovic, M. (2011) · British Medical Bulletin · doi:10.1093/bmb/ldr027 · Cited by 116 · cited 2×
“Additionally, MSCs express various chemokine receptors and after intravenous injection migrate to the tumor tissue to participate in the anti-tumor immune response [33].”
BackgroundGalland, S., Vuille, J., Martin, P., Letovanec, I., Caignard, A., Fregni, G., & Stamenkovic, I. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.089 · Cited by 109
Regulatory T Cells in Autoimmunity and Cancer: A Duplicitous Lifestyle
Hatzioannou, A., Boumpas, A., Papadopoulou, M., Papafragkos, I., Varveri, A., Alissafi, T., & Verginis, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.731947 · Cited by 106 · cited 1×
“Tregs express immunoregulatory molecules (PDL1 and CTLA4) and produce immunosuppressive cytokines (IL-10, IL-35, TGF-β), which inhibit the synthesis of TNF-α, IFN-γ and IL-17 in Th1 and Th17 cells and reduce the production of perforin and granzymes in CTLs, alleviating their anti-tumor properties [25].”
BackgroundBabajani, A., Soltani, P., Jamshidi, E., Farjoo, M. H., & Niknejad, H. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00748 · Cited by 99 · cited 8×
“Anti-neoplastic drug-loaded MSCs released chemotherapeutics directly in the site of primary and metastatic tumors without affecting neighboring tissues [44].”
BackgroundInfluentialLayek, B., Sadhukha, T., & Prabha, S. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.02.024 · Cited by 92
The Mechanism of Stimulating and Mobilizing the Immune System Enhancing the Anti-Tumor Immunity
Wu, Z., Li, S., & Zhu, X. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.682435 · Cited by 84 · cited 5×
“CTLs and NK cells express cell death ligands (program death ligand (PDL) and Fas ligand (FASL)), which activate extrinsic and intrinsic mitochondrial apoptotic pathways in malignant cells through the binding to program death (PD) and Fas receptors that are expressed on their membranes [1,4,5].”
BackgroundInfluentialLi, T., Wan, Y., Su, Z., Li, J., Han, M., & Zhou, C. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06458-1 · Cited by 80 · cited 1×
“Human BM-MSC-EV-sourced miRNA-16-5p and miRNA-3940-5p from human umbilical cord-derived MSC-EVs (UC-MSC-EVs) inhibited the migratory properties and metastatic potential of tumor cells by down-regulating the expression of Integrin Subunit Alpha (ITGA)2 and ITGA6 on their membranes [39,40].”
Backgroundde Lourdes Mora-García, M., García-Rocha, R., Morales-Ramírez, O., Montesinos, J. J., Weiss-Steider, B., Hernández-Montes, J., Ávila-Ibarra, L. R., Don-López, C. A., Velasco-Velázquez, M. A., Gutiérrez-Serrano, V., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1057-8 · Cited by 77
DCision-making in tumors governs T cell anti-tumor immunity
Alfei, F., Ho, P., & Lo, W. (2021) · Oncogene · doi:10.1038/s41388-021-01946-8 · Cited by 73 · cited 2×
“Critical aspects in the interaction between tumor and immune cells are the generation, expression and release of tumor antigens and their consequent engulfment and processing by dendritic cells (DCs) [2].”
BackgroundJia, X.-H., Feng, G.-W., Wang, Z.-L., Du, Y., Shen, C., Hui, H., Peng, D., Li, Z.-J., Kong, D.-L., & Tian, J. (2016) · Oncotarget · doi:10.18632/oncotarget.8064 · Cited by 62 · cited 10×
“The tumor-promoting activity of the MSCs in vivo was largely dependent on their capacity for enhanced production of CCL2, COX-2 and IL-6.”
BackgroundInfluentialSarhan, D., Wang, J., Arvindam, U. S., Hallstrom, C., Verneris, M. R., Grzywacz, B. J., Warlick, E. D., Blazar, B. R., & Miller, J. S. (2020) · JCI Insight · doi:10.1172/jci.insight.130155 · Cited by 59 · cited 2×
“IFN-γ, mainly derived from tumor-infiltrating Th1 lymphocytes and NK cells, is crucially important for the generation and immunosuppressive function of MDSCs [23].”
BackgroundChen, H., Li, J.-J., Jiang, F., Shi, W., & Chang, G. (2019) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2019.1677452 · Cited by 56 · cited 1×
“Human BM-MSC-EV-delivered miRNA4461 suppressed the proliferation and invasive properties of tumor cells by reducing the expression of COPB2, which is essential for Golgi budding and vesicular trafficking [41].”
BackgroundGazdic, M., Simovic Markovic, B., Jovicic, N., Misirkic-Marjanovic, M., Djonov, V., Jakovljevic, V., Arsenijevic, N., Lukic, M. L., & Volarevic, V. (2017) · Stem Cells International · doi:10.1155/2017/6294717 · Cited by 44 · cited 3×
“Exogenously administered MSCs use the same molecular and cellular mechanisms as CA-MSCs to suppress anti-tumor immunity [29].”
BackgroundSelf-citationSong, J., Eum, D., Park, S.-Y., Jin, Y., Shim, J.-W., Park, S.-J., Kim, M., Park, S.-J., Heo, K., & Choi, Y.-J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240533 · Cited by 44 · cited 1×
“MDSCs produce a large number of immunosuppressive molecules (Arginase-1, NO, TGF-β, IL-10) that inhibit the proliferation and activation of naïve T cells, induce apoptosis and promote the G0/G1 cell cycle arrest of effector Th1 and Th17 cells, attenuate the cytotoxicity of CTLs and NK cells, induce the alternative act…”
BackgroundA calcium optimum for cytotoxic T lymphocyte and natural killer cell cytotoxicity
Kaschek, L., Zöphel, S., Knörck, A., & Hoth, M. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.12.002 · Cited by 44 · cited 3×
“CTLs and NK cells express cell death ligands (program death ligand (PDL) and Fas ligand (FASL)), which activate extrinsic and intrinsic mitochondrial apoptotic pathways in malignant cells through the binding to program death (PD) and Fas receptors that are expressed on their membranes [1,4,5].”
BackgroundGhosh, T., Barik, S., Bhuniya, A., Dhar, J., Dasgupta, S., Ghosh, S., Sarkar, M., Guha, I., Sarkar, K., Chakrabarti, P., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30265 · Cited by 42 · cited 5×
“Ghosh and colleagues demonstrated that CA-MSCs in a paracrine, IL-10 and STAT3-dependent manner suppressed the DC-dependent activation of naïve T cells [14].”
BackgroundInfluentialLiu, L., Yu, T., Jin, Y., Mai, W., Zhou, J., & Zhao, C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.629893 · Cited by 42 · cited 2×
“Human adipose tissue-derived MSC-EVs (AT-MSC-EVs) carrying miRNA-15a inhibit the immune escape of tumor cells by regulating the expression of homeobox C4 (HOXC4), which binds to the promoter sequence of PDL1, controlling its synthesis and membrane expression [42].”
BackgroundFeng, H., Zhao, J., Schiergens, T. S., Wang, P., Ou, B., Al-Sayegh, R., Li, M.-L., Lu, A., Yin, S., & Thasler, W. E. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.415 · Cited by 41 · cited 4×
“Additionally, MSC-sourced TNFα induces the necrosis of tumor cells and enhances the expression of E and P selectins on tumor endothelial cells, enabling a massive influx of immune cells [36].”
BackgroundInfluentialRoles of Mesenchymal Stem Cell-Derived Exosomes in Cancer Development and Targeted Therapy
Sun, Z., Zhang, J., Li, J., Li, M., Ge, J., Wu, P., You, B., & Qian, H. (2021) · Stem Cells International · doi:10.1155/2021/9962194 · Cited by 41 · cited 2×
“Accordingly, MSC-EVs could deliver MSC-sourced anti-tumorigenic miRNAs directly into tumor cells, altering their viability, proliferation rate and invasive characteristics (Figure 2) [10,13].”
BackgroundMagistri, P., Leonard, S. Y., Tang, C., Chan, J. C., Lee, T. E., & Sicklick, J. K. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.12.010 · Cited by 37 · cited 1×
“Glypican 3 (GPC3) is a protein that regulates the proliferation of hepatocellular carcinoma cells [35].”
BackgroundT Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC
Szöőr, Á., Vaidya, A. B., Velasquez, M. P., Mei, Z., Galvan, D. L., Torres, D., Gee, A. P., Heczey, A. A., & Gottschalk, S. M. (2017) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2017.07.002 · Cited by 34
Mesenchymal Stem Cells and Myeloid Derived Suppressor Cells: Common Traits in Immune Regulation
Lyadova, I. V., Sosunova, E., Николаев, А. А., & Nenasheva, T. A. (2016) · Journal of Immunology Research · doi:10.1155/2016/7121580 · Cited by 31 · cited 14×
“Several lines of evidence demonstrated that both tumor-resident (cancer-associated MSCs (CA-MSCs)) and exogenously administered MSCs promoted tumor growth by: (i) preventing the DC-dependent activation of naive T cells, (ii) inducing the alternative activation of TAMs, (iii) modulating cytokine production in T helper…”
BackgroundInfluentialLayek, B., Shetty, M., Nethi, S. K., Sehgal, D. N., Starr, T. K., & Prabha, S. (2020) · Cancers · doi:10.3390/cancers12040965 · Cited by 30
Hamilton, G., & Plangger, A. (2021) · Biologics · doi:10.2147/btt.s290305 · Cited by 30 · cited 2×
“CTLs and NK cells express cell death ligands (program death ligand (PDL) and Fas ligand (FASL)), which activate extrinsic and intrinsic mitochondrial apoptotic pathways in malignant cells through the binding to program death (PD) and Fas receptors that are expressed on their membranes [1,4,5].”
BackgroundLiu, Z., Mi, F., Han, M., Tian, M., Deng, L., Meng, N., Luo, J., & Fu, R. (2021) · Clinical and Experimental Immunology · doi:10.1111/cei.13594 · Cited by 29 · cited 2×
“In line with these findings are results recently obtained by Liu and colleagues, who showed that the BM-MSC-dependent suppression of the anti-tumor properties of CTLs was crucially responsible for the progression of multiple myeloma (MM) [19].”
BackgroundResultGuo, S., Huang, C., Han, F., Chen, B., Ding, Y., Zhao, Y., Chen, Z., Wen, S., Wang, M., Shen, B., et al. (2021) · Stem Cells International · doi:10.1155/2021/9989790 · Cited by 28 · cited 2×
“The cross-talk between CA-MSCs and NK cells is crucially important for the optimal MSC-driven suppression of anti-tumor immunity [20].”
BackgroundThe Effects of Mesenchymal Stem Cell on Colorectal Cancer
Yuan, J., Wei, Z., Xu, X., Ocansey, D. K. W., Cai, X. J., & Mao, F. (2021) · Stem Cells International · doi:10.1155/2021/9136583 · Cited by 25 · cited 2×
“Since MSCs represent an important cellular constituent of the tumor microenvironment and are able to modulate the phenotype and function of all immune cells that participate in the anti-tumor immune response [9,10], a large number of experimental studies investigated the molecular mechanisms that were responsible for…”
BackgroundMiloradovic, D., Miloradovic, D., Marković, B. S., Acović, A., Harrell, C. R., Djonov, V., Arsenijević, N., & Volarević, V. (2020) · Stem Cells International · doi:10.1155/2020/8842659 · Cited by 16 · cited 5×
“In line with these findings, we recently observed that the effects of exogenously administered MSCs on anti-tumor immunity and tumor progression depended on the time of their inoculation in tumor-bearing animals [32].”
BackgroundResultSelf-citationMehdipour, F., Razmkhah, M., Rezaeifard, S., Bagheri, M., Talei, A., Khalatbari, B., & Ghaderi, A. A. (2018) · Cell Biology International · doi:10.1002/cbin.11062 · Cited by 15 · cited 2×
“In vivo, the CA-MSC-dependent induction of the regulatory phenotype in B cells contributed to the creation of systemic immunosuppression that enabled enhanced tumor growth and progression [28].”
BackgroundHeidari, F., Razmkhah, M., Razban, V., & Erfani, N. (2021) · Cell Biology International · doi:10.1002/cbin.11698 · Cited by 13 · cited 1×
“MSCs in an indoleamine 2,3-dioxygenase (IDO)-dependent manner induce the generation and expansion of Tregs [26,27].”
Background
Cited by
Targeting the tumor stroma for cancer therapy
Xu, M., Zhang, T., Xia, R., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01670-1 · Cited by 319
Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer
Liu, S., Zhang, X., Wang, W., Li, X., Sun, X., Zhao, Y., Wang, Q., Li, Y., Hu, F., & Ren, H. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02165-x · Cited by 246
Lyu, Z., Xin, M., Oyston, D. R., Xue, T., Kang, H., Wang, X., Wang, Z., & Wang, Z. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155354 · Cited by 70
The paradoxical role of radiation‐induced cGAS–STING signalling network in tumour immunity
Zhang, X., Zhang, H., Zhang, J., Yang, M., Zhu, M., Yin, Y., Fan, X., & Yu, F. (2022) · Immunology · doi:10.1111/imm.13592 · Cited by 71
“Although mesenchymal stromal cells (MSCs) exist in various tissues, including bone marrow, fat and dental pulp, MSCs derived from different tissues have similar immunomodulatory functions and tumour homing properties to some extent [102, 103].”
BackgroundSlama, Y., Ah-Pine, F., Khettab, M., Arcambal, A., Begue, M., Dutheil, F., & Gasque, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713511 · Cited by 57
Metadata
- Authors
- Harrell, C. R., Volarevic, A., Djonov, V. G., Jovicic, N., & Volarevic, V.
- Affiliations
- Regenerative Processing Plant, LLC, 34176 US Highway 19 N, Palm Harbor, FL 34684, USA
- University of Kragujevac (RS)
- University of Bern (CH)
- Department of Genetics, Faculty of Medical Sciences, University of Kragujevac, 69 Svetozar Markovic Street, 34000 Kragujevac, Serbia
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-11-18
- Volume
- 22
- Issue
- 22
- Pages
- 12429
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8622564
- OpenAlex
- W3213583932
- Cited by
- 67
- References
- 47
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 23 · 2023: 17 · 2022: 4
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- European Crohn’s and Colitis Organization (ECCO) (“The role of galectin 3 in acute colitis”)
- Swiss National Science Foundation (IZSEZ0 185546)
- Serbian Ministry of Science (ON1275069 and ON175071)
- Faculty of Medical Sciences University of Kragujevac (MP01/18)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- mesenchymal stem cells, antitumor immunity, tumor microenvironment, dendritic cells, macrophages, CD4+ T helper cells, CD8+ T cells, natural killer cells, myeloid-derived suppressor cells, regulatory T cells, tumor homing, exosomes, cancer immunotherapy
- MeSH terms
- Cell Communication, Cell Differentiation, Dendritic Cells, Gene Expression Regulation, Humans, Immunity, Innate, Immunotherapy, Killer Cells, Natural, Macrophages, Neoplasms, T-Lymphocytes, Cytotoxic, Mesenchymal Stem Cell Transplantation, T-Lymphocytes, Regulatory, Exosomes, Tumor Microenvironment, Mesenchymal Stem Cells, B7-H1 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.